New dye could help spot celiac disease during endoscopy
NCT ID NCT07377565
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early study tests a single oral dose of HB-2121 in 20 adults with suspected celiac disease. The dye is given four hours before a standard endoscopy to see how it interacts with the small intestine and whether it is safe. Researchers will track side effects and measure the dye's brightness in biopsy samples for up to 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HB-2121
What this could lead to
If successful, HB-2121 could become a new diagnostic tool to help doctors identify celiac disease more easily during routine endoscopy.
What could go wrong
This is a very early Phase 1 safety study with only 20 participants. It is not designed to prove the diagnostic works, only that it is safe. Many early-stage trials do not lead to approved tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States